Medifocus Inc. Announces Extension of Warrants
May 30 2014 - 4:28PM
Marketwired
Medifocus Inc. Announces Extension of Warrants
TORONTO, ONTARIO--(Marketwired - May 30, 2014) - Medifocus Inc.
(Medifocus or the Company) (TSX-VENTURE:MFS)(OTCQX:MDFZF) is
pleased to announce that it has applied to the TSX Venture Exchange
(the Exchange) to extend the expiry date of 18,367,253 outstanding
common share purchase warrants issued pursuant to the private
placement announced June 8, 2012 (the Warrants) by one year. Each
Warrant entitles the holder to acquire one common share of
Medifocus at a price of $0.20.
If the Exchange approves the extension, the Company will be
permitted to extend the term of the Warrants from June 8, 2014 to
June 8, 2015. All other terms and conditions of the Warrants will
remain unchanged and in full force and effect.
About Medifocus, Inc.
Medifocus owns two fully developed technology platforms with
comprehensive United States and international patent protection:
(i) The Endo-thermotherapy Platform-a catheter-basis focused heat
technology platform that utilizes natural body openings to deliver
precise microwave thermotherapy to the diseased sites. The United
States Food and Drug Administration (FDA) approved Prolieve
Thermodilatation System for the treatment of Benign Prostatic
Hyperplasia (BPH) was developed based on the Endo-thermotherapy and
is currently generating revenue; and (ii) the Adaptive Phased Array
(APA) Microwave Focusing Platform, invented by the Massachusetts
Institute of Technology, licensed to Medifocus, directs precisely
focused microwave energy at tumor center to induce shrinkage or
eradication of tumors without undue harm to surrounding tissue.
Medifocus' APA 1000 Breast Cancer Treatment System, developed from
the APA technology platform, has received approval from the FDA and
Health Canada to conduct the pivotal Phase III clinical trials.
Medifocus believes that these two technology platforms can provide
the design basis for the development of multiple cancer treatment
systems for surface, subsurface and deep seated localized and
regional cancers. Please visit www.medifocusinc.com,
www.prolieve.com and
http://www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627
for more details.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Medifocus Contact:Medifocus, Inc.John Mon,
COO410-290-5734JohnMon@medifocusinc.comInvestor Relations
Contact:Consulting for Strategic Growth 1Robert
Giordano917-327-3938rgiordanonyc@gmail.com
Medifocus (CE) (USOTC:MDFZF)
Historical Stock Chart
From Apr 2024 to May 2024
Medifocus (CE) (USOTC:MDFZF)
Historical Stock Chart
From May 2023 to May 2024
